Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.82 USD | +0.66% | -9.55% | +29.16% |
04-25 | Immunome, Inc. Appoints Sandra M. Swain to Board of Directors | CI |
04-15 | Guggenheim Starts Immunome With Buy Rating, $35 Price Target | MT |
Sales 2024 * | 8M 10.93M | Sales 2025 * | - | Capitalization | 828M 1.13B |
---|---|---|---|---|---|
Net income 2024 * | -114M -156M | Net income 2025 * | -149M -204M | EV / Sales 2024 * | 104 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.91
x | P/E ratio 2025 * |
-5.82
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
1 day | +0.66% | ||
1 week | -9.55% | ||
Current month | -44.00% | ||
1 month | -44.00% | ||
3 months | -28.39% | ||
6 months | +58.30% | ||
Current year | +29.16% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 01-01 |
Director/Board Member | 70 | 11-06 | |
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 13.82 | +0.66% | 786,908 |
24-04-26 | 13.73 | -3.72% | 967,621 |
24-04-25 | 14.26 | -0.07% | 737,149 |
24-04-24 | 14.27 | -2.66% | 555,483 |
24-04-23 | 14.66 | -4.06% | 891,857 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.16% | 823M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- IMNM Stock